13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001442756
Total reported value
$1.2B
$1.2B
79 檔
26.5%
In Q1 2026, PFM Health Sciences, LP's U.S. equity holdings reached a combined market value of $1.2B, distributed across 79 disclosed stock positions.
In Q1 2026, PFM Health Sciences, LP displayed an active expansion posture, initiating 21 new positions and adding to 39 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | THC | Tenet Healthcare CORP | Stock-Healthcare | 6.86% | -4.83% | +0.20% | |
| 2 | UTHR | United Therapeutics CORP | Stock-Healthcare | 6.35% | -4.03% | +73.31% | |
| 3 | LLY | Eli Lilly & Co | Stock-Healthcare | 5.52% | -1.48% | -3.70% | |
| 4 | XBI | Ss Spdr S&p Biotech ETF | ETF-Tech | 5.30% | -5.30% | EXIT | |
| 5 | PEN | Penumbra Inc | Stock-Healthcare | 4.19% | -2.56% | -3.71% | |
| 6 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 4.07% | +0.54% | +5.07% | |
| 7 | ASND | Ascendis Pharma A/S | Stock-Other | 3.64% | -3.64% | EXIT | |
| 8 | XLV | Ss Health Care Select Sector | ETF-Other | 3.19% | -3.19% | EXIT | |
| 9 | JAZZ | Jazz Pharmaceuticals plc | Stock-Healthcare | 3.07% | +0.25% | +252.68% | |
| 10 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 2.59% | +0.50% | +32.16% | |
| 11 | GKOS | Glaukos CORP | Stock-Healthcare | 2.12% | -2.12% | EXIT | |
| 12 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 1.91% | -1.91% | EXIT | |
| 13 | INBX | Inhibrx Biosciences Inc | Stock-Other | 1.87% | +0.64% | +15.03% | |
| 14 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 1.86% | +0.08% | +3.11% | |
| 15 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 1.75% | -0.13% | -15.91% | |
| 16 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 1.63% | -0.28% | +370.46% | |
| 17 | INDV | Indivior Pharmaceuticals Inc | Stock-Other | 1.60% | -0.19% | — | |
| 18 | ASND 2.25 04-01-28Bond | Ascendis Pharma A/s | Bond | 1.54% | -1.54% | EXIT | |
| 19 | UNH | Unitedhealth Group Inc | Stock-Healthcare | 1.43% | +1.72% | +14.84% | |
| 20 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 1.32% | -0.31% | +72.87% | |
| 21 | ABT | Abbott Laboratories | Stock-Healthcare | 1.31% | -0.67% | — | |
| 22 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 1.25% | +1.05% | -7.05% | |
| 23 | ACHC | Acadia Healthcare Co Inc | Stock-Other | 1.24% | +0.09% | — | |
| 24 | NEO | Neogenomics Inc | Stock-Healthcare | 1.21% | -1.21% | EXIT | |
| 25 | COO | Cooper Cos Inc/the | Stock-Healthcare | 1.11% | +0.25% | +68.48% | |
| 26 | NTRA | Natera Inc | Stock-Healthcare | 1.09% | -0.58% | — | |
| 27 | ITGR | Integer Holdings CORP | Stock-Healthcare | 1.08% | -0.06% | +26.74% | |
| 28 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 1.08% | -0.11% | +239.77% | |
| 29 | WAT | Waters CORP | Stock-Healthcare | 1.08% | +0.85% | -7.97% | |
| 30 | AMRX | Amneal Pharmaceuticals Inc | Stock-Other | 1.05% | -0.34% | -36.53% | |
| 31 | PRAX | Praxis Precision Medicines I | Stock-Other | 1.04% | +0.07% | +13.72% | |
| 32 | HSIC | Henry Schein Inc | Stock-Healthcare | 1.03% | -0.07% | — | |
| 33 | CGON | Cg Oncology Inc | Stock-Other | 1.02% | -0.24% | +1.19% | |
| 34 | MMSI | Merit Medical Systems Inc | Stock-Healthcare | 1.02% | +0.15% | — | |
| 35 | CLDX | Celldex Therapeutics Inc | Stock-Other | 0.94% | +0.15% | +144.03% | |
| 36 | BLTE | Belite Bio Inc - Adr | Stock-Other | 0.86% | -0.40% | +199.81% | |
| 37 | DXCM | Dexcom Inc | Stock-Healthcare | 0.86% | -0.86% | EXIT | |
| 38 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 0.83% | -0.83% | EXIT | |
| 39 | CNC | Centene CORP | Stock-Healthcare | 0.79% | +1.07% | -76.00% | |
| 40 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 0.78% | +0.07% | +39.24% | |
| 41 | ORKA | Oruka Therapeutics Inc | Stock-Other | 0.78% | +0.52% | — | |
| 42 | TNGX | Tango Therapeutics Inc | Stock-Other | 0.77% | +0.10% | — | |
| 43 | HCA | Hca Healthcare Inc | Stock-Healthcare | 0.77% | -0.49% | +29.47% | |
| 44 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 0.76% | -0.76% | EXIT | |
| 45 | BTSG | Brightspring Health Services | Stock-Other | 0.73% | +0.12% | +58.06% | |
| 46 | CMPS | Compass Pathways PLC | Stock-Other | 0.69% | -0.39% | +75.36% | |
| 47 | TMO | Thermo Fisher Scientific Inc | Stock-Healthcare | 0.66% | +0.57% | -60.88% | |
| 48 | NVO | Novo-nordisk A/s-spons Adr | Stock-Healthcare | 0.66% | +0.43% | — | |
| 49 | SYK | Stryker CORP | Stock-Healthcare | 0.66% | +0.87% | -56.82% | |
| 50 | VERA | Vera Therapeutics Inc | Stock-Other | 0.64% | +0.19% | +62.38% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | UTHR | United Therapeutics CORP | +3.1% | +73.31% | Add |
| 2 | JAZZ | Jazz Pharmaceuticals plc | +2.2% | +252.68% | Add |
| 3 | MDGL | Madrigal Pharmaceuticals Inc | +1.2% | +370.46% | Add |
| 4 | DNTH | Dianthus Therapeutics Inc | +0.9% | +72.87% | Add |
| 5 | RYTM | Rhythm Pharmaceuticals Inc | +0.7% | +239.77% | Add |
| 6 | CLDX | Celldex Therapeutics Inc | +0.6% | +144.03% | Add |
| 7 | BLTE | Belite Bio Inc - Adr | +0.5% | +199.81% | Add |
| 8 | 260 | Centessa Pharmaceuticals-adr | +0.4% | -10.71% | Trim |
| 9 | CGON | Cg Oncology Inc | +0.3% | +1.19% | Add |
| 10 | COO | Cooper Cos Inc/the | +0.3% | +68.48% | Add |
| 11 | BTSG | Brightspring Health Services | +0.3% | +58.06% | Add |
| 12 | TARS | Tarsus Pharmaceuticals Inc | +0.3% | +193.46% | Add |
| 13 | NBIX | Neurocrine Biosciences Inc | +0.3% | +32.16% | Add |
| 14 | ITGR | Integer Holdings CORP | +0.3% | +26.74% | Add |
| 15 | MLYS | Mineralys Therapeutics Inc | +0.2% | +199.51% | Add |
| 16 | CMPS | Compass Pathways PLC | +0.2% | +75.36% | Add |
| 17 | PRAX | Praxis Precision Medicines I | +0.1% | +13.72% | Add |
| 18 | HCA | Hca Healthcare Inc | +0.1% | +29.47% | Add |
| 19 | VKTX | Viking Therapeutics Inc | +0.1% | +39.24% | Add |
| 20 | VERA | Vera Therapeutics Inc | +0.1% | +62.38% | Add |
| 21 | GPCR | Structure Therapeutics Inc | +0.1% | +85.18% | Add |
| 22 | CGEM | Cullinan Therapeutics Inc | +0.1% | +0.18% | Add |
| 23 | RVMD | Revolution Medicines Inc | +0.1% | -7.05% | Trim |
| 24 | TECX | Tectonic Therapeutic Inc | 0% | +7.97% | Add |
| 25 | ASND 2.25 04-01-28Bond | Ascendis Pharma A/s | 0% | +7.98% | Add |
| 26 | AMLX | Amylyx Pharmaceuticals Inc | 0% | +7.97% | Add |
| 27 | CRBU | Caribou Biosciences Inc | 0% | — | Unchanged |
| 28 | SNDX | Syndax Pharmaceuticals Inc | 0% | +0.85% | Add |
| 29 | OM | Outset Medical Inc | 0% | +12.03% | Add |
| 30 | MDLN | Medline Inc-cl A | 0% | +2.09% | Add |
| 31 | RZLT | Rezolute Inc | 0% | -37.59% | Trim |
| 32 | QURE | uniQure N.V. | 0% | +7.94% | Add |
| 33 | MBX | Mbx Biosciences Inc | -0.1% | -9.35% | Trim |
| 34 | ARGX | Argenx Se - Adr | -0.1% | +7.92% | Add |
| 35 | BLLN | Billiontoone Inc Cl A | -0.1% | +0.60% | Add |
| 36 | PSNL | Personalis Inc | -0.1% | +7.98% | Add |
| 37 | ASND | Ascendis Pharma A/S | -0.1% | -1.83% | Trim |
| 38 | GKOS | Glaukos CORP | -0.2% | +6.95% | Add |
| 39 | ABVX | Abivax Sa-adr | -0.2% | -16.36% | Trim |
| 40 | OSCR | Oscar Health Inc - Class A | -0.2% | — | Unchanged |
| 41 | INBX | Inhibrx Biosciences Inc | -0.2% | +15.03% | Add |
| 42 | UNH | Unitedhealth Group Inc | -0.2% | +14.84% | Add |
| 43 | EW | Edwards Lifesciences CORP | -0.2% | +3.11% | Add |
| 44 | PEN | Penumbra Inc | -0.3% | -3.71% | Trim |
| 45 | SLNOEUR | Soleno Therapeutics Inc | -0.4% | +0.12% | Add |
| 46 | AXSM | Axsome Therapeutics Inc | -0.5% | +5.07% | Add |
| 47 | WAT | Waters CORP | -0.6% | -7.97% | Trim |
| 48 | BBIO | Bridgebio Pharma Inc | -0.6% | -15.91% | Trim |
| 49 | DXCM | Dexcom Inc | -0.6% | -34.14% | Trim |
| 50 | CAH | Cardinal Health Inc | -0.7% | -48.76% | Trim |
According to official SEC Form 13F filings, PFM Health Sciences, LP reported a total U.S. public equity portfolio value of $1.2B across 79 disclosed positions in Q1 2026.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including THC, UTHR, LLY) accounted for 26.5% of total reported equity market value during Q1 2026.
Top New Position Initiated
XBI
市值: $58.2M
Top Position Liquidated / Trimmed
ADMA
前期市值: $23.2M
During Q1 2026, PFM Health Sciences, LP's top holdings by market value included THC (6.9%)、UTHR (6.3%)、LLY (5.5%). The largest single position, THC, represented 6.9% of total portfolio value.
In Q1 2026, PFM Health Sciences, LP made 96 total portfolio adjustments, initiating 21 new buys, adding to 39 positions, trimming 17 holdings, and fully liquidating 19 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.